Q1 2023 Results slide image

Q1 2023 Results

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology Oncology Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 68 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation